Your browser is no longer supported. Please, upgrade your browser.
JAZZ Jazz Pharmaceuticals plc monthly Stock Chart
Jazz Pharmaceuticals plc
Index- P/E64.56 EPS (ttm)2.31 Insider Own3.10% Shs Outstand55.41M Perf Week0.82%
Market Cap8.31B Forward P/E8.92 EPS next Y16.71 Insider Trans2.12% Shs Float53.88M Perf Month6.70%
Income133.20M PEG9.29 EPS next Q4.07 Inst Own99.40% Short Float8.83% Perf Quarter30.70%
Sales2.22B P/S3.75 EPS this Y24.50% Inst Trans0.58% Short Ratio6.29 Perf Half Y32.52%
Book/sh56.70 P/B2.63 EPS next Y33.92% ROA2.40% Target Price169.94 Perf Year20.25%
Cash/sh30.40 P/C4.90 EPS next 5Y6.95% ROE4.40% 52W Range86.88 - 156.26 Perf YTD-0.23%
Dividend- P/FCF9.72 EPS past 5Y57.70% ROI12.80% 52W High-4.69% Beta1.20
Dividend %- Quick Ratio5.40 Sales past 5Y13.00% Gross Margin94.40% 52W Low71.42% ATR3.80
Employees1620 Current Ratio5.60 Sales Q/Q5.30% Oper. Margin8.90% RSI (14)55.98 Volatility2.43% 2.38%
OptionableYes Debt/Eq0.67 EPS Q/Q-54.90% Profit Margin6.00% Rel Volume0.46 Prev Close150.26
ShortableYes LT Debt/Eq0.66 EarningsNov 02 AMC Payout0.00% Avg Volume756.91K Price148.93
Recom1.80 SMA200.88% SMA506.97% SMA20021.22% Volume351,613 Change-0.89%
Oct-09-20Reiterated H.C. Wainwright Buy $175 → $185
Sep-14-20Resumed JP Morgan Overweight $175
Sep-14-20Downgrade Goldman Neutral → Sell $128
Aug-06-20Upgrade Morgan Stanley Equal-Weight → Overweight $177
Jul-28-20Upgrade Wolfe Research Peer Perform → Outperform
Jul-23-20Upgrade H.C. Wainwright Neutral → Buy
Apr-06-20Initiated Jefferies Buy $149
Mar-12-20Upgrade Bernstein Mkt Perform → Outperform $166
Jan-08-20Initiated Goldman Neutral $153
Aug-21-19Downgrade Piper Jaffray Overweight → Neutral $205 → $142
Jun-11-19Initiated Barclays Overweight $164
Mar-20-19Initiated SunTrust Buy $163
Dec-14-18Initiated Wolfe Research Peer Perform
Nov-08-18Reiterated B. Riley FBR Buy $219 → $190
Aug-08-18Reiterated Stifel Buy $180 → $205
Jul-11-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-23-18Reiterated H.C. Wainwright Neutral $150 → $160
Mar-19-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-03-18Initiated Leerink Partners Outperform $180
Dec-05-17Reiterated Mizuho Neutral $144 → $150
Oct-26-20 12:31PM  
Oct-20-20 07:30AM  
Oct-19-20 04:15PM  
Oct-18-20 06:36AM  
Oct-14-20 04:05PM  
Oct-10-20 03:00PM  
Oct-09-20 12:42PM  
Oct-08-20 04:18PM  
Oct-07-20 07:21AM  
Oct-05-20 11:40AM  
Oct-02-20 11:08AM  
Sep-24-20 02:52PM  
Sep-23-20 06:10AM  
Sep-17-20 11:40AM  
Sep-15-20 08:00AM  
Sep-14-20 10:01AM  
Sep-09-20 07:30AM  
Sep-08-20 04:05PM  
Sep-04-20 06:02PM  
Sep-03-20 11:31AM  
Sep-01-20 12:20PM  
Aug-27-20 08:36AM  
Aug-21-20 12:24PM  
Aug-05-20 12:10PM  
Aug-04-20 06:45PM  
Aug-03-20 12:12PM  
Jul-30-20 07:32PM  
Jul-28-20 12:33PM  
Jul-22-20 01:49PM  
Jul-21-20 04:05PM  
Jul-13-20 08:00AM  
Jul-12-20 12:53PM  
Jun-30-20 09:31AM  
Jun-18-20 02:19PM  
Jun-16-20 10:15AM  
Jun-15-20 03:35PM  
Jun-09-20 09:26AM  
Jun-08-20 07:00AM  
Jun-04-20 11:31AM  
May-30-20 06:01PM  
May-27-20 04:05PM  
May-14-20 09:53AM  
May-13-20 02:57PM  
May-11-20 08:30AM  
May-09-20 08:10AM  
May-08-20 01:11AM  
May-06-20 11:39AM  
May-05-20 06:45PM  
May-04-20 10:57AM  
May-03-20 07:36AM  
Apr-29-20 04:05PM  
Apr-28-20 12:33PM  
Apr-21-20 04:05PM  
Apr-17-20 02:16PM  
Apr-13-20 10:29AM  
Apr-07-20 06:40AM  
Mar-31-20 04:01PM  
Mar-26-20 11:30AM  
Mar-25-20 04:05PM  
Mar-23-20 12:48AM  
Mar-15-20 11:32AM  
Feb-27-20 08:45AM  
Feb-26-20 04:46PM  
Feb-25-20 06:45PM  
Feb-21-20 12:13PM  
Feb-17-20 02:30AM  
Feb-11-20 04:05PM  
Feb-03-20 03:46PM  
Jan-28-20 02:59AM  
Jan-27-20 12:10PM  
Jan-23-20 10:42AM  
Jan-22-20 08:00AM  
Jan-21-20 08:41AM  
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COZADD BRUCE CChairman & CEOOct 01Sale141.944,500638,730332,180Oct 05 07:21 PM
Larkin FinbarSVP, Technical OperationsSep 09Sale138.53638,72714,161Sep 10 06:48 PM
COZADD BRUCE CChairman & CEOSep 01Sale134.9050067,450336,680Sep 03 04:49 PM
COZADD BRUCE CChairman & CEOAug 27Sale130.003,000390,000337,180Aug 31 05:45 PM
Carr PatriciaVP, Finance & PAOAug 12Sale123.8014217,5806,200Aug 14 05:33 PM
Carr PatriciaVP, Finance & PAOAug 07Sale125.8715819,8876,342Aug 11 07:51 PM
Winningham Rick EDirectorAug 07Sale125.87931117,1856,198Aug 10 04:57 PM
Sohn Catherine A.DirectorAug 07Sale125.87931117,18610,622Aug 10 04:54 PM
RIEDEL NORBERT GDirectorAug 07Sale125.87931117,1869,459Aug 10 04:50 PM
O'Keefe Kenneth WDirectorAug 07Sale125.87931117,1867,418Aug 10 04:48 PM
McSharry Heather AnnDirectorAug 07Sale125.871,009127,00310,333Aug 10 04:45 PM
BERNS PAUL LDirectorAug 07Sale125.87931117,1859,740Aug 10 04:40 PM
Carr PatriciaVP, Finance & PAOJun 05Sale124.0013817,1126,500Jun 05 04:47 PM
Mulligan SeamusDirectorMay 27Buy111.2635,0003,894,0581,152,788May 27 06:36 PM
Mulligan SeamusDirectorMay 26Buy110.6515,0001,659,7471,117,788May 27 06:36 PM
Carr PatriciaVP, Finance & PAOMar 12Sale102.1760061,3026,500Mar 13 06:48 PM
MILLER MICHAEL PATRICKEVP, US CommercialMar 12Sale102.171,500153,25522,118Mar 13 06:46 PM
Larkin FinbarSVP, Technical OperationsMar 09Sale111.4961568,56613,883Mar 10 06:06 PM
Carr PatriciaVP, Finance & PAOMar 09Sale111.4556863,3037,100Mar 10 06:05 PM
Larkin FinbarSVP, Technical OperationsMar 06Sale119.1529234,79314,498Mar 10 06:06 PM
Carr PatriciaVP, Finance & PAOMar 06Sale119.1723227,6487,668Mar 10 06:05 PM
Carr PatriciaVP, Finance & PAOMar 04Sale118.6725330,0247,900Mar 05 07:42 PM
Larkin FinbarSVP, Technical OperationsMar 03Sale119.7527933,41014,790Mar 05 07:44 PM
Carr PatriciaVP, Finance & PAOMar 03Sale119.7524729,5788,153Mar 05 07:42 PM
COZADD BRUCE CChairman & CEOFeb 24Option Exercise11.486,89579,155305,783Feb 26 05:12 PM
MILLER MICHAEL PATRICKEVP, US CommercialFeb 13Sale142.181,500213,27026,571Feb 14 05:39 PM
COZADD BRUCE CChairman & CEOFeb 03Sale143.831,000143,830298,888Feb 05 04:28 PM
MILLER MICHAEL PATRICKEVP, US CommercialJan 13Sale146.781,500220,17028,071Jan 15 04:11 PM
COZADD BRUCE CChairman & CEOJan 02Sale149.611,250187,010299,888Jan 06 06:34 PM
MILLER MICHAEL PATRICKEVP, US CommercialDec 09Sale149.121,500223,68029,571Dec 10 06:06 PM
Carr PatriciaVP, Finance & PAODec 05Option Exercise123.361,667205,6417,549Dec 09 05:19 PM
Carr PatriciaVP, Finance & PAODec 05Sale148.931,749260,4855,800Dec 09 05:19 PM
O'Keefe Kenneth WDirectorDec 04Sale147.826,750997,7744,445Dec 06 07:11 PM
COZADD BRUCE CChairman & CEODec 02Sale150.0010,7501,612,500301,138Dec 04 05:51 PM
COZADD BRUCE CChairman & CEONov 05Sale130.0050065,000311,855Nov 07 06:53 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.